Beriate 500 IU powder

Marketed by Dexa Medica

Ingredients in every 5 ml

Coagulation Factor VIII 500 IU

Each package contains

1 vial of 5 ml

Other details

Dosage form:Powder for Injection
Flavour: None

W.H.O. classification

ATC Level 1: B - Blood and blood forming organs
ATC Level 2: B02 - Antihemorrhagics
ATC Level 3: B02B - Vitamin K and Other Hemostatics

Warnings

Pregnancy

CAUTIONThis item may not be safe for use during pregnancy. Use with caution and after consultation with your doctor.

Lactation

CAUTIONThis item may not be safe for use during lactation. Use with caution.

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

SAFE IF PRESCRIBEDThis item is safe for use while operating heavy machinery.

Available in

Indonesia

Dosage information

18 YEARS OLD AND ABOVE
The dosage and duration of the substitution therapy depend on the severity of the factor VIII deficiency, on the location and extent of the bleeding and on the patient’s clinical condition.
The number of units of factor VIII administered is expressed in International Units (IU), which are related to the current WHO standard for factor VIII products. Factor VIII activity in plasma is expressed either as a percentage (relative to normal human plasma) or in IU (relative to an International Standard for factor VIII in plasma).
One IU of factor VIII activity is equivalent to that quantity of factor VIII in one ml of normal human plasma.

Prophylaxis
For long term prophylaxis against bleeding in patients with severe haemophilia A, the usual doses are 20 to 40 IU of factor VIII per kg body weight at intervals of 2 to 3 days. In some cases, especially in younger patients, shorter dosage intervals or higher doses may be necessary.
During the course of treatment, appropriate determination of factor VIII levels is advised to guide the dose to be administered and the frequency of repeated infusions. In the case of major surgical interventions in particular, aprecise monitoring of the substitution therapy by means of coagulation analysis (plasma factor VIII activity) is indispensable. Individual patients may vary in their response to factor VIII, achieving different levels of in vivo recovery and demonstrating different half-lives. Patients should bemonitored for the development of factor VIII inhibitors.

For intravenous use.

The preparation should be warmed to room or body temperature before administration.
Inject or infuse slowly intravenously at a rate which the patient finds comfortable. The
injection or infusion rate should not exceed 2ml perminute.
Observe the patient for any immediate reaction. If any reaction takes place that might be
related to the administration of Beriate, the rate of infusion should be decreased or the
infusion stopped,as required by the clinical condition of the patient.

1 TO 18 YEARS OLD
Dosing in children is based on body weight and is therefore generally based on the same guidelines as for adults. The frequency of administration should always be oriented to the clinical effectiveness in the individual case.

For intravenous use.

The preparation should be warmed to room or body temperature before administration.
Inject or infuse slowly intravenously at a rate which the patient finds comfortable. The
injection or infusion rate should not exceed 2ml perminute.
Observe the patient for any immediate reaction. If any reaction takes place that might be
related to the administration of Beriate, the rate of infusion should be decreased or the
infusion stopped,as required by the clinical condition of the patient.

Indication

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).

Disclaimer

The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for informational purposes only. This tool may not cover all possible drug interactions or all warnings or alerts. Please check with a physician if you have health questions or concerns about interactions or go to the appropriate government authority for a comprehensive list of medical warnings. Although we attempt to provide accurate and up-to-date information, no guarantee is made to that effect.

All of the content present on this website, including written text, photographs, videos, graphics, and other resources we might include (these will fall under the collective term of “website”), is meant to educate and should not be perceived as a substitution for professional medical advice, diagnosis or treatment. You should not resort to the website information to arrive at a diagnosis or treatment solution for your health problems or various medical conditions. It does not replace medical care, provided by a medical specialist. In the situation, you have specific symptoms and you might suspect that you are suffering from a medical problem, it is for the best to consult your physician.